IV Therapy and NAD Clinics: How to Measure Whether Premium Infusion Protocols Are Actually Working

Premium infusion protocols, especially NAD-boosting IV therapy, are widely sold on the promise of cellular repair and slower aging. The only way to know whether that promise is being kept is to measure something that changes when inflammation and immune function change, not just something that measures the metabolite itself. An at-home biological age test that analyzes IgG glycosylation (the sugar patterns attached to antibodies that shift with chronic inflammation) gives clinics and clients a way to track whether an infusion protocol is producing a real biological effect, distinct from a felt one. Below are the questions clinic clients and IV/NAD practice owners most often ask once they start looking past the infusion bag and toward proof.

For a broader look at how this fits into your practice's testing and retention strategy, see GlycanAge for Healthcare Providers, Functional Medicine Clinics & Corporate Wellness Programs.

What Does "Working" Actually Mean for an NAD or IV Therapy Protocol?

"Working" should mean a measurable shift in the biology the protocol claims to affect, not just a subjective sense of more energy. NAD (nicotinamide adenine dinucleotide) is a molecule every cell needs for energy production and repair, and it declines with age, but restoring blood levels of NAD is not the same as confirming the restoration changed downstream aging biology. A 28-day, double-blinded, placebo-controlled crossover supplement trial (a design where each participant serves as their own control) measured NAD levels, the enzyme NAMPT that the body needs to keep making its own NAD, inflammatory cytokines, and glycation (a process where sugar molecules bind irreversibly to proteins, stiffening tissue) alongside biological age using GlycanAge, and recorded an average biological age reduction of 1.26 years over the intervention period in this specific 28-day trial population. That result matters because it connects a metabolic intervention to a measurable change in immune aging, not just to a self-reported feeling of vitality. Ask any clinic offering NAD therapy whether they track a biomarker like this before and after a protocol, not just NAD blood levels. 

Why Isn't a Simple NAD Blood Test Enough to Prove an IV Protocol Is Working?

Measuring circulating NAD tells you the molecule reached the bloodstream, not that it reached the cell or fixed the reason NAD was declining in the first place. NAD is both unstable outside the body and too large to move efficiently into cells, meaning infusions and injections can raise blood levels while the cell's own production machinery stays unrepaired. A human clinical trial addressing this directly showed that a supplement designed to restore the enzyme NAMPT, the cell's own NAD-manufacturing enzyme, produced a significant increase in NAD within two weeks, and a significant rise in NAMPT protein itself by day 28, evidence that the root cause of decline, not just the symptom, was being addressed. A rising number on an NAD blood panel cannot tell a clinic or client whether that root-cause repair happened. Tracking a biomarker of immune aging alongside NAD levels closes that gap. 

Can Raising NAD Levels Actually Backfire and Increase Inflammation?

Yes, boosting NAD without addressing how the body consumes it can drive inflammation rather than resolve it. CD38 is an enzyme that competes for available NAD and, when overactive, uses it up before the cell's repair pathways benefit, a pattern researchers say may explain some of the inflammatory issues reported with certain NAD precursor supplements. In the same 28-day human trial, participants on the CD38-inhibiting formulation showed a significant reduction in inflammatory cytokines compared to placebo, confirming the additional NAD was being routed toward beneficial pathways rather than fueling inflammation. This is precisely the mechanism GlycanAge is built to surface chronic, low-grade inflammation (inflammaging) that standard blood chemistry does not capture. 

"Glycosylation and glycans in general are something where inter-individual differences are really important. We're seeing that even with a very aggressive therapy like monoclonal antibodies against TNF, which shut down parts of the inflammatory pathway, glycosylation changes in maybe 30 to 50 percent of people. In the other 50 percent, it doesn't help, because the inflammation is running through a different pathway."

— Prof. Gordan Lauc, Co-Founder and Chief Scientific Officer, GlycanAge; Professor of Biochemistry and Molecular Biology, University of Zagreb 

This is exactly why a CD38-targeting or NAD-boosting protocol can't be assumed to work the same way for every client. Before assuming more NAD equals better outcomes, ask whether the protocol addresses CD38 activity, and track an inflammation-sensitive biomarker to confirm the direction of change for that individual. 

How Long Should a Clinic Wait Before Retesting to See a Protocol's Effect?

Meaningful biological age change from a targeted intervention can register within weeks under controlled trial conditions, but the retest interval a clinic builds into a protocol should be longer. The 28-day NAD supplement trial cited above recorded a measurable biological age reduction, glycation reduction, and cytokine reduction inside a single 28-day research window, using GlycanAge as the outcome biomarker, which shows the underlying biology can shift quickly. For pharmaceutical and other aggressive interventions, including IV and injectable NAD protocols, the standard retest window is 3 to 4 months, giving enough time for a stable, clinically meaningful reading rather than a single trial snapshot. Build that retest into the protocol itself, at baseline and again at 3 to 4 months, rather than as an afterthought once a client asks for proof. 

What's the Difference Between Glycation and Glycosylation, and Why Do Both Matter Here?

Glycation and glycosylation are distinct processes measuring different things, and confusing them leads to confusing conclusions about what an IV protocol has actually changed. Glycation is an unregulated, damaging process where a sugar molecule binds irreversibly to a protein, contributing to arterial stiffness and skin aging, and it can be reduced by interventions that lower oxidative and metabolic stress. IgG glycosylation, the process GlycanAge measures on IgG antibodies, is a regulated, biologically meaningful signal that shifts with immune function and inflammation, and its plasticity is what makes it useful for tracking whether a lifestyle or medical intervention is working. A clinic running an NAD protocol that measures serum glycation is capturing one dimension of aging; layering in a glycosylation-based biomarker captures the immune and inflammatory dimension that glycation alone does not reveal.

Is an NAD Supplement Trial Result the Same Thing as Evidence an IV Infusion Works?

No, and clinics should not conflate the two without checking the delivery method behind the evidence. The GlycanAge-linked biological age reduction and inflammatory improvements referenced above came from an oral supplement engineered to restore NAMPT enzyme activity and inhibit CD38, tested in a randomized, double-blinded, placebo-controlled crossover trial across a wide age range and both sexes, not from an IV or injectable NAD protocol. Whether an infused or injected NAD product produces the same root-cause repair and the same biological age response has not been established by the sources here. Clinics offering IV NAD should be direct with clients about what has and has not been measured for their specific delivery format, and should treat a biomarker like GlycanAge as the way to generate that evidence for their own protocol rather than borrowing someone else's.

How Should a Longevity or IV Clinic Use This Kind of Biomarker With Clients?

Use it as an objective referee that sits outside the protocol, giving both clinician and client a shared, independent read on whether the intervention changed the underlying biology. A practitioner who can show a client a biological age reading before a protocol and a lower one after is offering proof a supplement recommendation or a single infusion cannot: a repeatable signal tied to immune function and inflammation, not just to symptoms or how the client feels that week. That proof point is also what turns a single infusion visit into a longitudinal client relationship, since baselining before a protocol and retesting after creates a natural, evidence-based reason to return. For a clinic deciding which biomarker earns a place in its protocol library, the ability to validate outcomes objectively is the difference between a wellness add-on and a credible clinical tool.

What Should I Ask My IV or NAD Clinic Before Starting a Premium Protocol?

Ask what baseline measurement the clinic takes before the protocol starts and what it plans to remeasure afterward, beyond a subjective symptom check-in. A clinic confident in its protocol should be able to name a specific biomarker it uses to validate effectiveness, describe the expected retest window, and explain the mechanism the protocol is meant to affect, whether that's NAD synthesis, CD38 activity, or downstream inflammation. 

"I'm a doctor who has moved from prescribing pills to prescribing lifestyle. Biological age is a critical piece of data that I now measure in all of my clients, and using accurate, personalized data to drive that decision-making is so important."

— Dr. Alka Patel, GP, Lifestyle Medicine Doctor, Author, and Podcaster 

If a clinic cannot answer these questions, that is worth noting before committing to a premium, recurring protocol. A baseline glycan-based biological age reading, followed by a retest after the protocol series, gives a documented answer instead of an assumption.

This is where an at-home biological age test earns its place in a serious longevity or IV protocol: not as another wellness add-on, but as the evidence layer that tells you and your clinician whether the intervention changed anything real.

Clinics building an evidence-based IV or longevity offering can bring GlycanAge into their protocol library to baseline clients, validate outcomes, and support recurring retests. Visit the Healthcare Providers page to see how clinics integrate GlycanAge into intervention tracking. 

Partner with us to add a validated, independent outcome measure to your practice.

External sources

• https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ — Henderson JD, Quigley SNZ, Chachra SS, Conlon N, Ford D. The use of a systems approach to increase NAD+ in human participants. npj Aging. 2024;10(1):7.